# Diphtheria Antitoxin (equine)

**Revision Date:** April 17, 2014

Please consult the Product Leaflet for further information about this product.

<table>
<thead>
<tr>
<th><strong>Diphtheria Antitoxin (equine)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Manufacturer</strong></td>
</tr>
<tr>
<td>VINS Bioproducts Limited, India</td>
</tr>
</tbody>
</table>

**Authorization and access**

Special authorization and access procedures must be followed.

- The Office of the Chief Medical Officer of Health (OCMOH) must be notified by the fastest means possible of all cases in which diphtheria antitoxin is required
- Available on a 24-hour basis from Alberta Health by calling OCMOH pager: 780-638-3630. A Special Access Program (SAP) Form is included with the product and must be completed and returned to Alberta Health.

**Note:** Diphtheria Antitoxin (equine) is stocked in the Provincial Vaccine Depot.

**Indications for use of diphtheria antitoxin serum**

Treatment of suspected (based on clinical symptoms) or confirmed disease. Bacteriologic confirmation is not required to initiate treatment.¹

**Note:** Not recommended for prophylaxis of close, unimmunized contacts of diphtheria cases.¹,²

For further information about the disease and reporting requirements refer to: *Public Health Notifiable Disease Management Guidelines – Diphtheria.*³

**Dose**

The therapeutic dose is determined by the severity of the disease.¹

Follow the dosage as outlined on the Product Leaflet.

This is a treatment product administered under the direction of a physician in an acute care setting.

**Note:** Diphtheria antitoxin is supplied in 10 mL vials containing 10,000 IU each. For example the product leaflet recommends 10,000 – 30,000 IU for mild to moderately severe cases and up to a maximum of 100,000 IU for severe cases.¹

**Route**

Refer to the Product Leaflet.

**Schedule**

- Diphtheria antitoxin serum should be administered as soon as possible after clinical diagnosis. Treatment should not await laboratory confirmation of toxigenic *C. diphtheriae*.
- Skin testing for serum hypersensitivity should be carried out before diphtheria antitoxin is administered.¹,²

Refer to the product information and Annex A and B of *Public Health Notifiable Disease Management Guidelines – Diphtheria.*³

**Note:** Individuals who have recovered from diphtheria should receive the age-appropriate diphtheria-containing vaccine. The vaccine should be administered three to four weeks after diphtheria antitoxin was administered to minimize antigen-antibody antagonism.⁵ Diphtheria does not necessarily confer immunity.²,⁴
<table>
<thead>
<tr>
<th>Pregnancy</th>
<th>Pregnancy is not a contraindication to the use of diphtheria antitoxin serum. Intact IgG crosses the placenta from maternal circulation increasingly after 30 weeks.(^5)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lactation</td>
<td>Breastfeeding is not a contraindication to diphtheria antitoxin serum. It is not known if antitoxin antibodies are excreted into breast milk.(^5)</td>
</tr>
</tbody>
</table>

References